Agios Pharmaceuticals, Inc. (AGIO)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Symbol
- AGIO
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.04B
- 52 week range
- 22.24 - 46
Valuation
- Share price
- $34.19 (close of 2026-09-23)
- P/E (TTM)
- -4.87x
- Price to book
- 1.99x
- Price to free cash flow
- -5.58x
- Enterprise value
- $1.07B
- Book value per share
- $17.21
Price performance
| Period | Change |
|---|
| 1 day | +0.71% |
| 5 days | +4.21% |
| 1 month | +3.32% |
| 3 months | -3.93% |
| 6 months | +21.63% |
| Year to date | +25.61% |
| 1 year | -9.72% |
| 3 years | +39.38% |
| 5 years | -28.40% |
| 10 years | -35.53% |
| All time | +9.30% |
Profitability and growth
- Return on equity
- -34.60%
- Return on invested capital
- -1413.87%
- Return on assets
- -31.82%
- Return on capital employed
- -38.86%
- Gross margin
- 88.26%
- Net margin
- -764.01%
- EBITDA margin
- -864.24%
- Revenue growth
- 48.03%
- Net income growth
- -161.27%
- Free cash flow growth
- 3.64%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -17.92%
- Current ratio
- 10.22x
- Net debt to EBITDA
- 2.14x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $54.03M
- Cost of revenue
- $6.34M
- Gross profit
- $47.68M
- EBITDA
- $-466.93M
- Net income
- $-412.78M
- Earnings per share
- $-7.12
- Research and development
- $339.54M
- Shares outstanding
- 57.97M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $54.03M | $47.68M | $-412.78M | $-7.12 |
| 2024-12-31 | $36.50M | $32.33M | $673.73M | $11.86 |
| 2023-12-31 | $26.82M | $23.94M | $-352.09M | $-6.33 |
| 2022-12-31 | $14.24M | $12.54M | $-231.80M | $-4.23 |
| 2021-12-31 | - | - | $1.60B | $26.55 |
| 2020-12-31 | - | - | $-327.37M | $-4.74 |
| 2019-12-31 | $117.91M | $116.59M | $-411.47M | $-6.86 |
| 2018-12-31 | $94.39M | $92.99M | $-346.03M | $-6.03 |
| 2017-12-31 | $43.01M | - | $-314.67M | $-6.75 |
| 2016-12-31 | $69.89M | - | $-198.47M | $-5.07 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 88.26% | -764.01% | -34.60% | -1413.87% |
| 2024-12-31 | 88.59% | 1845.92% | 43.72% | -434.67% |
| 2023-12-31 | 89.26% | -1312.63% | -43.41% | -510.98% |
| 2022-12-31 | 88.03% | -1627.82% | -21.06% | -449.91% |
| 2021-12-31 | - | - | 124.21% | -368.58% |
| 2020-12-31 | - | - | -81.94% | - |
| 2019-12-31 | 98.88% | -348.97% | -64.24% | -869.11% |
| 2018-12-31 | 98.52% | -366.61% | -50.33% | - |
| 2017-12-31 | - | -731.60% | -83.80% | - |
| 2016-12-31 | - | -283.97% | -55.35% | - |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $1.20B |
| 2024-12-31 | $1.50B |
| 2023-12-31 | $806.40M |
| 2022-12-31 | $1.10B |
| 2021-12-31 | $1.29B |
| 2020-12-31 | $670.50M |
| 2019-12-31 | $717.80M |
| 2018-12-31 | $805.40M |
| 2017-12-31 | $567.80M |
| 2016-12-31 | $573.60M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-377.29M | $52.55M |
| 2024-12-31 | $-391.53M | $42.85M |
| 2023-12-31 | $-297.06M | $44.77M |
| 2022-12-31 | $-314.36M | $49.30M |
| 2021-12-31 | $-413.06M | $53.51M |
| 2020-12-31 | $-304.87M | $61.60M |
| 2019-12-31 | $-382.65M | $58.05M |
| 2018-12-31 | $-311.41M | $73.36M |
| 2017-12-31 | $-289.86M | $47.81M |
| 2016-12-31 | $28.65M | $42.09M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-29
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-30 | Jun/2026 | - |
| 2026-04-29 | - | - |
| 2026-02-12 | - | - |
| 2025-10-30 | - | - |
| 2025-07-31 | - | - |
| 2025-05-01 | - | - |
| 2025-02-13 | - | - |
| 2024-10-31 | - | - |
Filings and sources
- Company website
- agios.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades